Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment

被引:1
作者
Saeed, Nabiha [1 ]
Khan, Zurrya [1 ]
Jehanzeb, Hamzah [2 ]
Shaikh, Taha [2 ]
Shaikh, Usman [3 ]
Adil, Salman N. [3 ]
Madni, Varisha [2 ]
Fatima, Hania [2 ]
Abiha, Umm E. [1 ]
Ali, Natasha [3 ]
机构
[1] Aga Khan Univ Hosp, Dept Oncol, Karachi, Pakistan
[2] Aga Khan Univ, Dept Oncol, Med Coll, Karachi, Pakistan
[3] Aga Khan Univ Hosp, Dept Pathol & Lab Med Oncol, Karachi, Pakistan
关键词
Categories; Oncology; Hematology bortezomib; transplant ineligible; proteasome inhibitors; triplet regimen; newly diagnosed multiple myeloma; STEM-CELL TRANSPLANTATION; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; BORTEZOMIB; DEXAMETHASONE; INDUCTION; THERAPY;
D O I
10.7759/cureus.58999
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Multiple myeloma (MM) is a hematological disorder characterized by aberrant multiplication of malignant plasma cells in the bone marrow. The current mainstay of treatment for patients with newly diagnosed MM (NDMM) is a triplet regimen with a proteasome inhibitor, immunomodulatory imide, and dexamethasone. The two most common of these triplet regimens are VLD (bortezomib/lenalidomide/dexamethasone) and VCD (bortezomib/cyclophosphamide/dexamethasone). This study aims to compare the outcomes between these two therapies in transplant -ineligible patients with NDMM. Methods We conducted a retrospective study at the Aga Khan University Hospital in Karachi, Pakistan. All NDMM transplant -ineligible patients either receiving VLD or VCD therapy between January 2015 and December 2022 were included in our study. Hematological parameters before and after treatment were obtained from hospital records. Response to treatment was classified according to the International Myeloma Working Group (IMWG) response criteria as either complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD), or progressive disease (PD). The response to treatment as well as overall survival (OS) and progression -free survival (PFS) was compared between VCD and VLD therapy. A p -value of 0.05 or less was taken to be statistically significant. Results Twenty (23.8%) patients in the VCD group and 20 (23.0%) in the VLD group underwent complete remission. Seven (8.3%) patients experienced disease progression in the VCD group, while the figure stood at three (3.4%) in the VLD group. There was no statistically significant difference in the overall response rate between the VCD (58; 69.0%) and VLD (70; 80.5%) groups (p=0.086), a difference that was not statistically significant on the Chi-square test. OS was comparable between VCD (69.1 months, 95%CI: 61.3-77.0) and VLD (76.9 months, 95%CI: 69.0-85.0) therapies. Conclusions The study did not identify any statistically significant distinction in the treatment outcomes between the VCD and VLD regimens among NDMM patients ineligible for transplantation. Nevertheless, the study highlights the positive outcomes observed with both treatments in this specific patient cohort. This implies that either regimen could be deemed suitable as a treatment option for patients in low- and middle -income countries. Since both regimens demonstrate comparable effectiveness, assessing the cost-effectiveness of these regimens is crucial. Future research should also explore the economic aspects of the two treatment options.
引用
收藏
页数:10
相关论文
共 17 条
[1]   Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation [J].
Afrough, Aimaz ;
Pasvolsky, Oren ;
Ma, Junsheng ;
Srour, Samer ;
Bashir, Qaiser ;
Saini, Neeraj ;
Hosing, Chitra ;
Popat, Uday R. ;
Kebriaei, Partow ;
Delgado, Ruby ;
Ullah, Muhammad R. ;
Murphy, Regan ;
Manasanch, Elisabet E. ;
Lee, Hans C. ;
Kaufman, Gregory P. ;
Patel, Krina K. ;
Thomas, Sheeba K. ;
Weber, Donna M. ;
Orlowski, Robert Z. ;
Shpall, Elizabeth J. ;
Champlin, Richard E. ;
Qazilbash, Muzaffar H. .
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (06) :307.e1-307.e8
[2]  
Albagoush S. A., 2023, Multiple Myeloma
[3]  
[Anonymous], 2023, Notification S.R.O. 1092(l)2023
[4]   Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J].
Cavo, Michele ;
Tacchetti, Paola ;
Patriarca, Francesca ;
Petrucci, Maria Teresa ;
Pantani, Lucia ;
Galli, Monica ;
Di Raimondo, Francesco ;
Crippa, Claudia ;
Zamagni, Elena ;
Palumbo, Antonio ;
Offidani, Massimo ;
Corradini, Paolo ;
Narni, Franco ;
Spadano, Antonio ;
Pescosta, Norbert ;
Deliliers, Giorgio Lambertenghi ;
Ledda, Antonio ;
Cellini, Claudia ;
Caravita, Tommaso ;
Tosi, Patrizia ;
Baccarani, Michele .
LANCET, 2010, 376 (9758) :2075-2085
[5]   Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial [J].
Dimopoulos, Meletios A. ;
Gay, Francesca ;
Schjesvold, Fredrik ;
Beksac, Meral ;
Hajek, Roman ;
Weisel, Katja Christina ;
Goldschmidt, Hartmut ;
Maisnar, Vladimir ;
Moreau, Philippe ;
Min, Chang Ki ;
Pluta, Agnieszka ;
Chng, Wee-Joo ;
Kaiser, Martin ;
Zweegman, Sonja ;
Mateos, Maria-Victoria ;
Spencer, Andrew ;
Iida, Shinsuke ;
Morgan, Gareth ;
Suryanarayan, Kaveri ;
Teng, Zhaoyang ;
Skacel, Tomas ;
Palumbo, Antonio ;
Dash, Ajeeta B. ;
Gupta, Neeraj ;
Labotka, Richard ;
Rajkumar, S. Vincent ;
Bar, Daniel ;
Basso, Alfredo ;
Fantl, Dorotea ;
He, Simon ;
Horvath, Neomi ;
Lee, Cindy ;
Rowlings, Phillip ;
Taylor, Kerry ;
Cochrane, Tara ;
Kwok, Fiona ;
Ramanathan, Sundreswran ;
Agis, Hermine ;
Zojer, Niklas ;
Kentos, Alain ;
Offner, Fritz ;
Van Droogenbroeck, Jan ;
Wu, Ka Lung ;
Maiolino, Angelo ;
Martinez, Gracia ;
Zanella, Karla ;
Capra, Marcelo ;
Araujo, Sergio ;
Gregora, Evzen ;
Pour, Ludek .
LANCET, 2019, 393 (10168) :253-264
[6]   International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma [J].
Kumar, Shaji ;
Paiva, Bruno ;
Anderson, Kenneth C. ;
Durie, Brian ;
Landgren, Ola ;
Moreau, Philippe ;
Munshi, Nikhil ;
Lonial, Sagar ;
Blade, Joan ;
Mateos, Maria-Victoria ;
Dimopoulos, Meletios ;
Kastritis, Efstathios ;
Boccadoro, Mario ;
Orlowski, Robert ;
Goldschmidt, Hartmut ;
Spencer, Andrew ;
Hou, Jian ;
Chng, Wee Joo ;
Usmani, Saad Z. ;
Zamagni, Elena ;
Shimizu, Kazuyuki ;
Jagannath, Sundar ;
Johnsen, Hans E. ;
Terpos, Evangelos ;
Reiman, Anthony ;
Kyle, Robert A. ;
Sonneveld, Pieter ;
Richardson, Paul G. ;
McCarthy, Philip ;
Ludwig, Heinz ;
Chen, Wenming ;
Cavo, Michele ;
Harousseau, Jean-Luc ;
Lentzsch, Suzanne ;
Hillengass, Jens ;
Palumbo, Antonio ;
Orfao, Alberto ;
Rajkumar, S. Vincent ;
Miguel, Jesus San ;
Avet-Loiseau, Herve .
LANCET ONCOLOGY, 2016, 17 (08) :E328-E346
[7]   Review of 1027 patients with newly diagnosed multiple myeloma [J].
Kyle, RA ;
Gertz, MA ;
Witzig, TE ;
Lust, JA ;
Lacy, MQ ;
Dispenzieri, A ;
Fonseca, R ;
Rajkumar, SV ;
Offord, JR ;
Larson, DR ;
Plevak, ME ;
Therneau, TM ;
Greipp, PR .
MAYO CLINIC PROCEEDINGS, 2003, 78 (01) :21-33
[8]   Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance [J].
Kyle, Robert A. ;
Larson, Dirk R. ;
Therneau, Terry M. ;
Dispenzieri, Angela ;
Kumar, Shaji ;
Cerhan, James R. ;
Rajkumar, S. Vincent .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (03) :241-249
[9]   Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis [J].
Landgren, O. ;
Weiss, B. M. .
LEUKEMIA, 2009, 23 (10) :1691-1697
[10]   Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study [J].
Landgren, Ola ;
Kyle, Robert A. ;
Pfeiffer, Ruth M. ;
Katzmann, Jerry A. ;
Caporaso, Neil E. ;
Hayes, Richard B. ;
Dispenzieri, Angela ;
Kumar, Shaji ;
Clark, Raynell J. ;
Baris, Dalsu ;
Hoover, Robert ;
Rajkumar, S. Vincent .
BLOOD, 2009, 113 (22) :5412-5417